Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06826092
PHASE2

Metformin for the Treatment of mCRC Patients Undergoing FOLFIRI Plus Target Therapy

Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital

View on ClinicalTrials.gov

Summary

To investigate progression-free survival (PFS) in patients with metastatic colorectal cancer treated with chemotherapy FOLFIRI monotherapy or chemotherapy FOLFIRI combined with Metformin

Official title: Metformin as an Adjunctive Therapy for the Treatment of Metastatic Colorectal Cancer Patients Undergoing FOLFIRI Plus Target Therapy

Key Details

Gender

All

Age Range

20 Years - 90 Years

Study Type

INTERVENTIONAL

Enrollment

110

Start Date

2022-10-31

Completion Date

2025-12-31

Last Updated

2025-02-13

Healthy Volunteers

No

Interventions

DRUG

Metformin Pill

Metformin 500mg TID、FOLFIRI (Leucovorin 200 mg/m2、5-FU 2800 mg/m2、Irinotecan 180 mg/m2) plus target therapy

DRUG

FOLFIRI plus target therapy only

FOLFIRI (Leucovorin (LV), 200 mg/m2, 2-hour infusion, 5-FU, 2,800 mg/m2, 46-hour infusion, Irinotecan (IRI), 180 mg/m2, 2-hour infusion) plus target therapy

Locations (1)

Chung-Ho Memorial Hospital, Kaohsiung Medical University:

Kaohsiung City, Taiwan